Rani Therapeutics Holdings, INC 10-Q quarterly reports

Rani Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development and a Nasdaq listing deficiency notice.

Rani Therapeutics reported reduced net losses and secured over $75 million in new funding and potential milestones, alleviating prior going concern doubts and advancing its oral drug delivery platform.

Rani Therapeutics Holdings, Inc. reported continued losses and substantial doubt about its ability to continue as a going concern, alongside receiving notices of non-compliance with Nasdaq's minimum bid price and market value requirements.

Rani Therapeutics reports Q1 2025 results with a net loss of $12.7 million and expresses substantial doubt about its ability to continue as a going concern, despite preclinical advancements in its oral drug delivery platform.

Rani Therapeutics reported a net loss of $12.7 million for the third quarter of 2024, with substantial doubt raised about the company's ability to continue as a going concern.

Rani Therapeutics' second quarter 2024 results show a net loss of $13.361 million, with ongoing efforts to advance their oral delivery technology and secure additional funding.

Rani Therapeutics reported a net loss of $14.8 million for the first quarter of 2024 and highlighted progress in clinical trials and manufacturing.